Retrospective analysis shows shorter time to castration resistance worsens overall survival in mCSPC, suggesting ARSI therapy benefits patients with longer resistance times.
Key Points
Shorter time to castration resistance is significantly linked to poorer overall survival outcomes in patients with metastatic castration-sensitive prostate cancer.
Median overall survival from diagnosis was 70.6 months, while from progression to castration-resistant cancer it was 48.1 months.
Kaplan–Meier analysis identified that androgen receptor signaling inhibitors improved overall survival post-progression, especially in patients with longer resistance times.
These findings indicate that time to castration resistance could be a vital prognostic factor in mCSPC treatment decisions.